Vinblastine Sulfate

• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 Phase II/III 10 countries University Medical Center Hamburg-Eppendorf
• Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Pending
  2024-516896-34-00 Phase I/II 5 countries Universitaetsklinikum Heidelberg AöR
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 Phase III 1 country Polska Grupa Badawcza Chloniakow
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting
  2024-512503-39-00 Phase IV 3 countries Medizinische Hochschule Hannover
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting
  2022-500031-37-00 Phase III 7 countries University College London
• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 Phase II 1 country Les Hopitaux Universitaires De Strasbourg
• MetroWilms Recruiting
  2022-502687-20-00 Phase II 1 country Centre Oscar Lambret
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica… Recruiting
  2022-501454-11-00 Phase III 8 countries GPOH gGmbH
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended
  2024-512676-36-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended
  2024-510742-13-00 Phase III 16 countries Day One Biopharmaceuticals Inc.
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended
  2023-504821-38-00 Phase II 8 countries Merck Sharp & Dohme LLC
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended
  2023-508478-27-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended
  2023-505509-18-00 Phase III 7 countries Universitaetsklinikum Muenster AöR
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended
  2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
• Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with ref… Ended
  2024-513470-22-00 Phase I/II 1 country Centre Oscar Lambret
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 Phase III 9 countries Takeda Development Center Americas Inc.

Showing 1–18 of 18 trials